Polyhydramnios in the Third Trimester

Definition and Diagnostic Criteria

• Polyhydramnios is defined by ultrasound measurements as either a maximal vertical pocket (MVP) ≥8 cm or an amniotic fluid index (AFI) ≥25 cm or >95th percentile for gestational age, according to the American College of Radiology 1, 2, 3
• The MVP measurement may be preferable to AFI as it results in fewer false-positive diagnoses and unnecessary interventions while maintaining equivalent detection of adverse outcomes, as recommended by the American College of Radiology 2

Clinical Significance and Mortality Risk

• Polyhydramnios carries substantial perinatal risk, including an independent risk factor for stillbirth with odds ratios ranging from 1.8 to 5.8 depending on severity and presence of other anomalies, as reported by the American College of Radiology 1, 2, 3
• In a large cohort of over 200,000 singleton births, polyhydramnios was independently associated with stillbirth (OR 1.8; 95% CI 1.4-2.2), according to the American College of Radiology 3
• Isolated polyhydramnios (without fetal anomalies) has lower perinatal mortality than cases with additional fetal abnormalities, but risk remains elevated, as noted by the American College of Radiology 2

Twin-Specific Causes

• Twin-twin transfusion syndrome (TTTS) is a cause of polyhydramnios, characterized by the recipient twin developing polyhydramnios (MVP >8 cm) while the donor develops oligohydramnios (MVP <2 cm), as described by the American Journal of Obstetrics and Gynecology 4
• TTTS requires specialized evaluation and surveillance, with monitoring at least every 2 weeks starting at 16 weeks, and more frequent monitoring if pathology develops, as recommended by the American Journal of Obstetrics and Gynecology 4

Important Clinical Pitfalls

• Polyhydramnios may be transient, but even mild cases carry increased stillbirth risk, though lower than cases with anomalies, as reported by the American College of Radiology 2, 3
• In twin pregnancies, polyhydramnios requires immediate assessment for TTTS, which has stage-dependent prognosis and may require specialized intervention, as noted by the American Journal of Obstetrics and Gynecology 4

Management of Polyhydramnios with Severe Maternal Discomfort or Dyspnea

Diagnostic Evaluation and Treatment Approaches

• The American College of Obstetricians and Gynecologists recommends amnioreduction for severe maternal discomfort or dyspnea in the setting of severe polyhydramnios, involving the removal of amniotic fluid using an 18-20 gauge needle, typically reducing MVP to 5-6 cm 5, 6
• The Society for Maternal-Fetal Medicine suggests that repeated amnioreductions increase risks of preterm premature rupture of membranes, preterm labor, abruption, infection, and fetal death 5, 6
• Amnioreduction may be used after 26 weeks, particularly for maternal respiratory distress or preterm contractions, as recommended by the American Journal of Obstetrics and Gynecology 5, 6
• Fetoscopic laser photocoagulation of placental anastomoses is the definitive treatment for TTTS, with amnioreduction used for symptomatic relief but not definitive therapy 5, 6

Special Circumstances

• The American College of Obstetricians and Gynecologists recommends against the use of indomethacin for the sole purpose of decreasing amniotic fluid in polyhydramnios, due to the risk of oligohydramnios and premature closure of the ductus arteriosus 5, 6

Polyhydramnios Management Guidelines

Indications for MFM Referral

• Twin pregnancies with polyhydramnios should be referred immediately to assess for twin-twin transfusion syndrome (TTTS), which affects 10-20% of monochorionic twins and requires specialized evaluation and potential fetoscopic laser surgery 7
• Polyhydramnios with fetal structural anomalies requires MFM consultation for genetic counseling, consideration of chromosomal microarray analysis, and coordinated delivery planning 8
• Cases requiring amnioreduction should be managed at tertiary centers given the 15% complication rate within 48 hours and need for multidisciplinary approach 7

Diagnostic Evaluation

• Detailed anatomic ultrasound should be performed to identify fetal anomalies, as up to 20% of early-onset cases have structural or chromosomal abnormalities 8

Risk Stratification and Management

• Preterm delivery occurs in up to 66% of cases with polyhydramnios, and preterm labor <37 weeks occurs in 48.8% of cases requiring amnioreduction 9
• The American College of Obstetricians and Gynecologists recommends immediate assessment for TTTS with MFM consultation in twin pregnancies with any polyhydramnios 7

Polyhydramnios Causes and Complications

Fetal Causes

• Bartter syndrome is virtually always the cause when polyhydramnios results from excessive fetal polyuria, with severe polyhydramnios occurring in types 1, 2, 4a, and 4b, and very severe polyhydramnios in type 4b 10, 11, 12
• No other inherited tubular disorders cause severe polyhydramnios; notably, polyhydramnios is not a feature of severe proximal tubulopathies or nephrogenic diabetes insipidus 10, 11
• Cases initially misdiagnosed as pseudohypoaldosteronism type I with polyhydramnios have later been shown to harbor KCNJ1 mutations underlying Bartter syndrome type 2 10, 11

Therapeutic Amnioreduction: Indications, Benefits, Risks, and Timing

Indications for Amnioreduction

• Severe maternal respiratory distress or dyspnea caused by polyhydramnios is a primary indication for therapeutic amnioreduction, independent of the underlying cause. 13
• Preterm uterine contractions secondary to over‑distension from polyhydramnios may be alleviated by fluid removal. 13
• The procedure typically reduces a maximal vertical pocket (MVP) from > 8 cm to approximately 5–6 cm using an 18–20 gauge needle. 14

Twin‑Twin Transfusion Syndrome (TTTS) – Specific Scenarios

Temporizing Measure When Referral Is Delayed

• Amnioreduction can be used as a bridge to definitive fetoscopic laser therapy when geographic, financial, or patient‑driven factors delay referral to a fetal care center. [15][16]
• This bridge is justified only when severe maternal symptoms from polyhydramnios require urgent relief before laser surgery can be arranged. [15][16]

Limitations of Pre‑Referral Amnioreduction

• Registry data show a 15 % complication rate within 48 hours after amnioreduction for TTTS, with complications (PPROM, amnion‑chorion separation, bleeding, labor) that may preclude subsequent laser surgery. 17

Late‑Presenting TTTS (> 26 weeks)

• For TTTS diagnosed after 26 weeks gestation, when laser surgery, expectant management, or medically indicated delivery are not feasible, amnioreduction becomes a primary management strategy rather than merely a temporizing step. 17
• In this gestational window, amnioreduction is reserved for cases that do not qualify for laser therapy or immediate delivery. 15

Early‑Stage TTTS (Stage I–II)

• A single amnioreduction resolves TTTS in 20–30 % of Stage I–II cases, a rate that is not statistically superior to expectant management. 18
• Serial amnioreduction (re‑intervention when MVP > 8 cm) has largely been replaced by laser therapy for more advanced disease. 19

Mechanism of Benefit

• Fluid removal lowers intra‑amniotic and placental intravascular pressures, which is associated with a median 74 % increase in uterine artery volume flow after the procedure. 13
• By reducing uterine over‑distension, amnioreduction decreases the risk of preterm labor and preterm birth related to polyhydramnios. 18

Risks and Limitations

• Serial amnioreduction is linked to higher rates of preterm premature rupture of membranes (PPROM), preterm labor, placental abruption, infection, and fetal death. 19
• Any invasive procedure performed before fetoscopic laser may compromise the feasibility and success of laser therapy due to bleeding, chorioamnion separation, inadvertent septostomy, or membrane rupture. 19
• Amnioreduction is palliative, not curative, because it does not address the underlying placental vascular anastomoses in TTTS. 14
• Reported overall survival after amnioreduction for TTTS ranges from 50 % (average) to 60–65 % in large registries, which is inferior to outcomes after laser surgery. 13

Contraindications / When Not to Perform Amnioreduction

• Do not perform amnioreduction in TTTS cases before 26 weeks that are candidates for laser surgery, unless severe maternal symptoms demand urgent intervention and laser therapy is unavailable. 17
• Avoid amnioreduction when it would delay or complicate referral to a fetal care center for definitive laser therapy. 15
• Amnioreduction should not be used as primary therapy for advanced‑stage TTTS (Stages III–IV) presenting before 26 weeks, where laser surgery offers superior outcomes. 17

Timing Considerations

• Therapeutic amnioreduction can be performed any time after 14 weeks gestation. 13
• It is most commonly indicated after 26 weeks for TTTS management or for symptomatic polyhydramnios at any gestational age. 15